FDA approves daraxonrasib as Elicio preps Phase 1 trial combining it with camupepimut
Revolution Medicines' RAS inhibitor gains approval in metastatic pancreatic cancer as Elicio targets a fourth-quarter combination study start and reports Q3 results.
FDA, SEC filing (3)